Cargando…

PPARγ2 Pro12Ala polymorphism was associated with favorable cardiometabolic risk profile in HIV/HCV coinfected patients: a cross-sectional study

BACKGROUND: Peroxisome proliferator-activated receptor gamma-2 gene (PPARγ2) rs1801282 (Pro12Ala) polymorphism has been associated with lower risk of metabolic disturbance and atherosclerosis. The aim of this study was to analyze the association between the Pro12Ala polymorphism and cardiometabolic...

Descripción completa

Detalles Bibliográficos
Autores principales:	García-Broncano, Pilar, Berenguer, Juan, Fernández-Rodríguez, Amanda, Pineda-Tenor, Daniel, Jiménez-Sousa, María Ángeles, García–Alvarez, Mónica, Miralles, Pilar, Aldámiz-Echevarria, Teresa, López, Juan Carlos, Micheloud, Dariela, Resino, Salvador
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282155/ https://www.ncbi.nlm.nih.gov/pubmed/25159899 http://dx.doi.org/10.1186/s12967-014-0235-9

Ejemplares similares

Stroke in HIV-infected individuals with and without HCV coinfection in Spain in the combination antiretroviral therapy era
por: Alvaro-Meca, Alejandro, et al.
Publicado: (2017)

FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients
por: Pineda-Tenor, Daniel, et al.
Publicado: (2014)

Soluble Adhesion Molecules in Patients Coinfected with HIV and HCV: A Predictor of Outcome
por: Aldámiz-Echevarría, Teresa, et al.
Publicado: (2016)

Association between IL7R polymorphisms and severe liver disease in HIV/HCV coinfected patients: a cross-sectional study
por: Guzmán-Fulgencio, María, et al.
Publicado: (2015)

European mitochondrial haplogroups predict liver-related outcomes in patients coinfected with HIV and HCV: a retrospective study
por: Aldámiz-Echevarría, Teresa, et al.
Publicado: (2019)

Mx1, OAS1 and OAS2 polymorphisms are associated with the severity of liver disease in HIV/HCV-coinfected patients: A cross-sectional study
por: García-Álvarez, Mónica, et al.
Publicado: (2017)

Can serum hyaluronic acid replace simple non-invasive indexes to predict liver fibrosis in HIV/Hepatitis C coinfected patients?
por: Resino, Salvador, et al.
Publicado: (2010)

Successful HCV Therapy Reduces Liver Disease Severity and Inflammation Biomarkers in HIV/HCV-Coinfected Patients With Advanced Cirrhosis: A Cohort Study
por: Medrano, Luz Maria, et al.
Publicado: (2021)

ADAR1 polymorphisms are related to severity of liver fibrosis in HIV/HCV-coinfected patients
por: Medrano, Luz M., et al.
Publicado: (2017)

Prognostic value of liver stiffness in HIV/HCV-Coinfected patients with decompensated cirrhosis
por: Pérez-Latorre, Leire, et al.
Publicado: (2018)

Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients
por: Medrano, Luz M., et al.
Publicado: (2016)

Dysregulation of the Immune System in HIV/HCV-Coinfected Patients According to Liver Stiffness Status
por: Garcia-Broncano, Pilar, et al.
Publicado: (2018)

Trends in pulmonary embolism in patients infected with HIV during the combination antiretroviral therapy era in Spain: A nationwide population-based study
por: Alvaro-Meca, Alejandro, et al.
Publicado: (2018)

HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients
por: Brochado-Kith, Óscar, et al.
Publicado: (2021)

Telomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals (†)
por: Molina-Carrión, Silvia, et al.
Publicado: (2020)

HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients
por: Brochado, Óscar, et al.
Publicado: (2021)

Prevalence of hepatitis E infection in HIV/HCV-coinfected patients in Spain (2012–2014)
por: Vázquez-Morón, Sonia, et al.
Publicado: (2019)

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR
por: Vigón, Lorena, et al.
Publicado: (2019)

All‐oral direct‐acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV–coinfected subjects in real‐world practice: Madrid coinfection registry findings
por: Berenguer, Juan, et al.
Publicado: (2018)

Plasma IP-10 and IL-6 are linked to Child-Pugh B cirrhosis in patients with advanced HCV-related cirrhosis: a cross-sectional study
por: Salgüero, Sergio, et al.
Publicado: (2020)

HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1
por: Berenguer, Juan, et al.
Publicado: (2019)

Rate of candidiasis among HIV-infected children in Spain in the era of highly active antiretroviral therapy (1997–2008)
por: Álvaro-Meca, Alejandro, et al.
Publicado: (2013)

Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis
por: Pineda-Tenor, Daniel, et al.
Publicado: (2015)

Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019
por: Fanciulli, Chiara, et al.
Publicado: (2022)

Epidemiological trends of sepsis in the twenty-first century (2000–2013): an analysis of incidence, mortality, and associated costs in Spain
por: Álvaro-Meca, Alejandro, et al.
Publicado: (2018)

Liver Stiffness Hinders Normalization of Systemic Inflammation and Endothelial Activation after Hepatitis C Virus (HCV) Eradication in HIV/HCV Coinfected Patients
por: Álvarez, Beatriz, et al.
Publicado: (2020)

Managing HCV/HIV coinfection
por: Danish, Fazal A., et al.
Publicado: (2009)

Pharmacologic management of HCV treatment in patients with HCV monoinfection vs. HIV/HCV coinfection: Does coinfection really matter?
por: Zuckerman, Autumn D., et al.
Publicado: (2019)

Real-world Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) for 8 weeks in Patients Coinfected with HCV and HIV-1
por: Ruane, Peter, et al.
Publicado: (2017)

Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection
por: Macías, Juan, et al.
Publicado: (2015)

Liver Enzyme Alterations in HCV-Monoinfected and HCV/HIV-Coinfected Patients
por: Langohr, Klaus, et al.
Publicado: (2008)

Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV
por: Tseng, Chih-Wei, et al.
Publicado: (2022)

Comparison of methods and characterization of small RNAs from plasma extracellular vesicles of HIV/HCV coinfected patients
por: Martínez-González, Elena, et al.
Publicado: (2020)

Pro12Ala PPAR-γ2 and +294T/C PPAR-δ Polymorphisms and Association with Metabolic Traits in Teenagers from Northern Mexico
por: Carrillo-Venzor, Martín A., et al.
Publicado: (2020)

Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis
por: Merchante, Nicolás, et al.
Publicado: (2015)

Therapeutic issues in HIV/HCV-coinfected patients
por: Sulkowski, M S, et al.
Publicado: (2007)

Virological Mechanisms in the Coinfection between HIV and HCV
por: Liberto, Maria Carla, et al.
Publicado: (2015)

Evidence for Implementation: HIV/HCV Coinfection and Pregnancy
por: Curtis, Megan Rose, et al.
Publicado: (2023)

TRPM5 rs886277 Polymorphism Predicts Hepatic Fibrosis Progression in Non-Cirrhotic HCV-Infected Patients
por: Resino, Salvador, et al.
Publicado: (2021)

HCV coinfection contributes to HIV pathogenesis by increasing immune exhaustion in CD8 T-cells
por: Rallón, Norma, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jg49thp7v8r5cevjlfqh7lnmcs